Tetiana Tyzhnenko
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tetiana Tyzhnenko has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Kateryna Misiura
SI «V. Danilevsky Institute for Endocrine pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
14 shared publications - Maryana Gorshunska
V.N. Karazin Kharkiv National University, Kharkiv, Ukraine
9 shared publications - Zhanna Leshchenko
SI “V. Danilevsky Institute for Endocrine Pathology Problems of NAMS of Ukraine”, Kharkiv, Ukraine
9 shared publications - Alla Kolesnikova
SI «V. Danilevsky Institute for Endocrine pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
7 shared publications - Nataliya Krasova
SI «V. Danilevsky Institute for Endocrine pathology Problems of the NAMS of Ukraine», Kharkiv, Ukraine
6 shared publications - Igor A. Lurin
National Academy of Medical Sciences of Ukraine, Kyiv, Ukraine
5 shared publications
Latest Publications
- Open Access
- 14 November 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (7) , 715-722
The potential role of the SLC22A1 rs628031 A>G polymorphism in the pathogenetic mechanisms of hormonal and metabolic response to antihyperglycemic therapy
Background. Metformin is widely used as a first-line antihyperglycemic therapy in patients with type 2 diabetes mellitus (T2DM); however, individual variability in treatment response remains an important clinical issue. Genetic variations in the solute carrier family 22 member 1 (SLC22A1) gene, encoding the organic cation transporter 1 (OCT1), may influence metformin pharmacokinetics and metabolic effects. The purpose of this study was to evaluate the potential role of the SLC22A1 rs628031 A>G (Met408Val) polymorphism in the pathogenetic mechanisms of hormonal and metabolic responses to antihyperglycemic therapy in patients with T2DM and obesity. Materials and methods. The study included 61 patients with T2DM aged 28–80 years (35 men and 26 women) with metabolic syndrome and obesity (body mass index ≥ 30 kg/m2). All patients received oral antihyperglycemic therapy, including metformin, sulfonylureas, or their combinations. According to the antihyperglycemic therapy received, the patients were retrospectively divided into two groups: those receiving metformin-based therapy and those treated with other glucose-lowering agents (sulfonylureas or their combinations without metformin). Clinical, anthropometric, biochemical, hormonal, and metabolic parameters were assessed, including carbohydrate and lipid metabolism indices, liver function markers, adipokine profile, and oxidative stress parameters. Genotyping of the SLC22A1 rs628031 A>G polymorphism was performed using polymerase chain reaction and restriction fragment length polymorphism analysis with MscI restriction enzyme. Results. Metformin-based therapy was associated with favorable changes in glycemic control, lipid profile, adipokine status, and oxidative stress markers in patients with T2DM and obesity. Carriers of the AG genotype of the SLC22A1 rs628031 polymorphism receiving metformin demonstrated significantly lower levels of low-density lipoprotein cholesterol, total cholesterol, omentin, osteoprotegerin, alanine aminotransferase, and aspartate aminotransferase compared with other genotype groups. At the same time, AG genotype carriers showed higher omentin and osteoprotegerin concentrations compared with AA genotype carriers, suggesting genotype-dependent modulation of metformin-associated metabolic effects. Conclusions. The obtained results indicate that the SLC22A1 rs628031 A>G polymorphism may contribute to variability in hormonal and metabolic responses to metformin therapy in patients with T2DM and obesity. Genetic differences in OCT1 function may influence lipid metabolism, adipokine regulation, liver homeostasis, and potentially bone-related metabolic processes. Assessment of SLC22A1 genetic variants may contribute to the development of personalized approaches for optimizing antihyperglycemic therapy and improving metabolic outcomes in patients with diabetes and metabolic disorders.
- 14 November 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (7) , 715-722
Open AccessThe potential role of the SLC22A1 rs628031 A>G polymorphism in the pathogenetic mechanisms of hormonal and metabolic response to antihyperglycemic therapy
Background. Metformin is widely used as a first-line antihyperglycemic therapy in patients with type 2 diabetes mellitus (T2DM); however, individual variability in treatment response remains an important clinical issue. Genetic variations in the solute carrier family 22 member 1 (SLC22A1) gene, encoding the organic cation transporter 1 (OCT1), may influence metformin pharmacokinetics and metabolic effects. The purpose of this study was to evaluate the potential role of the SLC22A1 rs628031 A>G (Met408Val) polymorphism in the pathogenetic mechanisms of hormonal and metabolic responses to antihyperglycemic therapy in patients with T2DM and obesity. Materials and methods. The study included 61 patients with T2DM aged 28–80 years (35 men and 26 women) with metabolic syndrome and obesity (body mass index ≥ 30 kg/m2). All patients received oral antihyperglycemic therapy, including metformin, sulfonylureas, or their combinations. According to the antihyperglycemic therapy received, the patients were retrospectively divided into two groups: those receiving metformin-based therapy and those treated with other glucose-lowering agents (sulfonylureas or their combinations without metformin). Clinical, anthropometric, biochemical, hormonal, and metabolic parameters were assessed, including carbohydrate and lipid metabolism indices, liver function markers, adipokine profile, and oxidative stress parameters. Genotyping of the SLC22A1 rs628031 A>G polymorphism was performed using polymerase chain reaction and restriction fragment length polymorphism analysis with MscI restriction enzyme. Results. Metformin-based therapy was associated with favorable changes in glycemic control, lipid profile, adipokine status, and oxidative stress markers in patients with T2DM and obesity. Carriers of the AG genotype of the SLC22A1 rs628031 polymorphism receiving metformin demonstrated significantly lower levels of low-density lipoprotein cholesterol, total cholesterol, omentin, osteoprotegerin, alanine aminotransferase, and aspartate aminotransferase compared with other genotype groups. At the same time, AG genotype carriers showed higher omentin and osteoprotegerin concentrations compared with AA genotype carriers, suggesting genotype-dependent modulation of metformin-associated metabolic effects. Conclusions. The obtained results indicate that the SLC22A1 rs628031 A>G polymorphism may contribute to variability in hormonal and metabolic responses to metformin therapy in patients with T2DM and obesity. Genetic differences in OCT1 function may influence lipid metabolism, adipokine regulation, liver homeostasis, and potentially bone-related metabolic processes. Assessment of SLC22A1 genetic variants may contribute to the development of personalized approaches for optimizing antihyperglycemic therapy and improving metabolic outcomes in patients with diabetes and metabolic disorders.
- Open Access
- 2 October 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (6) , 599-604
Plasma atherogenic index as a non-invasive criterion for the diagnosis of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus
Background. Identification of risk factors and detection of target organs in the early stages of the formation of cardiovascular diseases, liver and kidney diseases and other complications with the correction of identified disorders is an integral part of the successful reduction of morbidity and mortality among the population. Diabetes mellitus (DM) is a syndrome of various etiologies, characterized mainly by chronic hyperglycemia with disorders associated with protein and lipid metabolism. The purpose of the study was to determine the presence and nature of the relationship of a new indirect index with the presence (or absence) of metabolically associated steatotic fatty liver disease (MASLD) in patients with T2DM, to determine the contribution of the atherogenic index of plasma (AIP) to the risk of developing liver disease and to characterize its diagnostic value using logistic regression and ROC analysis. Materials and methods. Sixty patients with T2DM were examined (33/27 men/women; age 53.00 ± 1.20 years; disease duration 13.36 ± 3.49 years), of them 24 participants with MASLD and 36 without it. The diagnosis of MASLD was established on the basis of clinical analysis of the disease, lipid and carbohydrate metabolism indicators, aspartate aminotransferase and alanine aminotransferase activity and ultrasound examination of the liver. Results. A significant and statistically significant relationship was found between the AIP and the presence of metabolically associated fatty liver disease. A distinct and significant correlation was established between the AIP and glycemia, as well as some indicators of oxidative stress (in particular, the index of free fatty acids and OXY levels) and the level of lipocalin, an adipokine. A diagnostic model was developed to identify risk groups for the development of MASLD in patients with T2DM based on the AIP. Conclusions. A diagnostic model was developed to form risk groups for MASLD among patients with T2DM using logistic regression and ROC analysis. The diagnostic criterion is a new non-invasive indicator — the AIP, the threshold value of the predictor is defined as 0.60.
- 2 October 2026
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 22 (6) , 599-604
Open AccessPlasma atherogenic index as a non-invasive criterion for the diagnosis of metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus
Background. Identification of risk factors and detection of target organs in the early stages of the formation of cardiovascular diseases, liver and kidney diseases and other complications with the correction of identified disorders is an integral part of the successful reduction of morbidity and mortality among the population. Diabetes mellitus (DM) is a syndrome of various etiologies, characterized mainly by chronic hyperglycemia with disorders associated with protein and lipid metabolism. The purpose of the study was to determine the presence and nature of the relationship of a new indirect index with the presence (or absence) of metabolically associated steatotic fatty liver disease (MASLD) in patients with T2DM, to determine the contribution of the atherogenic index of plasma (AIP) to the risk of developing liver disease and to characterize its diagnostic value using logistic regression and ROC analysis. Materials and methods. Sixty patients with T2DM were examined (33/27 men/women; age 53.00 ± 1.20 years; disease duration 13.36 ± 3.49 years), of them 24 participants with MASLD and 36 without it. The diagnosis of MASLD was established on the basis of clinical analysis of the disease, lipid and carbohydrate metabolism indicators, aspartate aminotransferase and alanine aminotransferase activity and ultrasound examination of the liver. Results. A significant and statistically significant relationship was found between the AIP and the presence of metabolically associated fatty liver disease. A distinct and significant correlation was established between the AIP and glycemia, as well as some indicators of oxidative stress (in particular, the index of free fatty acids and OXY levels) and the level of lipocalin, an adipokine. A diagnostic model was developed to identify risk groups for the development of MASLD in patients with T2DM based on the AIP. Conclusions. A diagnostic model was developed to form risk groups for MASLD among patients with T2DM using logistic regression and ROC analysis. The diagnostic criterion is a new non-invasive indicator — the AIP, the threshold value of the predictor is defined as 0.60.
- Open Access
- 15 March 2026
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 83 (1) , 14-22
EFFECT OF SIRT1 GENE POLYMORPHISM (rs2273773) ON CARDIOVASCULAR RISK MARKERS IN OVERWEIGHT PATIENTS WITH TYPE 2 DIABETES MELLITUS OF THE EAST UKRAINIAN POPULATION
There is evidence that sirtuins as energy sensors contribute to the pathogenesis of obesity and related metabolic and cardiovascular diseases in humans. The single nucleotide polymorphism (SNP) C > T (rs2273773) of the SIRT1 gene is a so-called «silent» mutation in exon 5 and may be linked to other mutations that affect both sirtuin-1 protein levels and its activity. The aim of the study was to assess the association of polymorphic variants rs2273773 of the sirtuin-1 gene with characteristics of insulin resistance and hormonal activity of adipose tissue in overweight patients with type 2 diabetes from the East Ukrainian population. Materials and methods. The study was conducted in accordance with international and domestic ethical and legal requirements and was approved by the Medical Ethics Committee at the IEPP. All examined patients underwent inpatient treatment at the institute's clinic. A retrospective analysis of clinical and biochemical parameters obtained for patients whose samples are included in the DNA collection of patients with type 2 diabetes mellitus (DM) was conducted. 61 patients with type 2 DM (male/female: 27/34) aged 53.35 ± 1.38 years, with diabetes duration of 5.33 ± 0.67 years, glycosylated hemoglobin level of 7.74 ± 0.19%, with body mass index of 33.28 ± 0.89 kg/m2, and with waist-to-hip ratio of 0.99 ± 0.01 were selected. Antidiabetic therapy included sulfonamides, biguanides, or their combinations. Clinical, biochemical, and enzyme-linked immunosorbent assay measurements were performed at the National Institute for Public Health and the Environment (Bilthoven, the Netherlands) within the framework of scientific cooperation. Insulin resistance was characterized by the HOMA-IR index, HOMA-IR/adiponectin, adiponectin/leptin, HOMA-IR/leptin, Adipo-IR and a number of other surrogate indices. The pathological impact of dyslipidemia was assessed by Castelli risk indices I and II and triglyceride-glucose index. Determination of the single-nucleotide substitution of cytosine for thymine in exon 5 of the SIRT1 gene rs2273773 (C > T) was carried out by polymerase chain reaction with two pairs of opposite primers. Electrophoretic fractionation determined the following genotypes for the rs2273773 (C > T) SIRT1 gene: CC — 314/228 bp; CT — 314/228/135 bp; TT — 314/135 bp. Allele frequencies for the studied genotype were calculated. The normality of the distribution of variables was determined using the Kolmogorov-Smirnov criterion. To compare the indicators characterized by normal distribution, the unpaired two-tailed Student's t-test was used, to compare the parameters with non-normal distribution, the Mann-Whitney test. To statistically assess the differences observed between the empirical and theoretical frequencies of the variation series, the χ2 (chi-square) test was used. Results. Genotyping according to the above-mentioned SNP indicates that there is no accumulation of certain genotypes under the conditions of the studied pathology. A preliminary analysis of the polymorphism functional significance was performed using a recessive inheritance model, i.e. CC-carriers (n = 24) versus CT + TT (n = 37). Analysis of clinical parameters revealed that this SNP did not have a statistically significant effect on the age of manifestation of type 2 DM, the degree of diabetes compensation, HOMA-IR, atherogenicity indices, blood pressure, and degree of obesity. However, there was a trend (0.05 < P < 0.1) towards worse indicators characterizing insulin resistance of adipose tissue (HOMA-IR/adiponectin, HOMA-IR/leptin, adiponectin/leptin) in carriers of the mutant T-allele. The above was accompanied by a shift in the triglyceride-glucose index (CC-carriers: 8.15 (4.29; 14.81) units vs 10.91 (6.88; 16.39) units in the CC + CT group, 0.05 < P < 0.1) and dyslipidemia parameters (triglycerides, high-density lipoprotein cholesterol). The mutant T-allele has been found to have a negative effect on indicators related to the hormonal function of adipose tissue. Thus, there is a statistically significant decrease in the levels of the most active form of anti-inflammatory adipocytokine — high molecular weight adiponectin — in T-allele carriers relative to the indicator for the CC genotype (1.96 ± 0.19 vs 3.09 ± 0.50 mg/L, respectively, P < 0.05). This was accompanied by a decrease in the levels of vaspin, an adipokine that increases insulin sensitivity, inhibits the synthesis of pro-inflammatory cytokines, and is involved in the regulation of food intake (CC-carriers: 0.33 (0.20; 0.64) vs 0.19 (0.08; 0.49) μg/L in the CC + CT group, P < 0.05). There are trends toward higher levels of chronic inflammation markers (TNF-α, IL-6, and IL-1b), which, however, do not reach statistical significance. In addition, carriers of the T-allele had significantly higher superoxide dismutase activity (24.77 ± 0.92 vs 20.46 ± 0.68 kU/mmol Hb in CC-carriers, P < 0.01) and levels of total (44.24 ± 3.45 vs 31.39 ± 2.96 μmol/mmol Hb in CC-carriers, P < 0.01) and reduced glutathione (35.10 ± 2.96 vs 21.86 ± 2.24 μmol/mmol Hb in CC-carriers, P < 0.01) in erythrocytes. The above is most likely compensatory in nature and indicates active lipoperoxidation processes. Conclusions. Analysis of the hormonal activity of adipose tissue suggests a higher cardiovascular risk in carriers of the minor allele of the C > T rs2273773 polymorphism of the sirtuin-1 gene among overweight patients with type 2 diabetes in the East Ukrainian population. The results obtained can be used to optimize prevention and treatment regimens for overweight individuals and patients with type 2 diabetes, which will help maintain working capacity and increase the duration and quality of life.
- 15 March 2026
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 83 (1) , 14-22
Open AccessEFFECT OF SIRT1 GENE POLYMORPHISM (rs2273773) ON CARDIOVASCULAR RISK MARKERS IN OVERWEIGHT PATIENTS WITH TYPE 2 DIABETES MELLITUS OF THE EAST UKRAINIAN POPULATION
There is evidence that sirtuins as energy sensors contribute to the pathogenesis of obesity and related metabolic and cardiovascular diseases in humans. The single nucleotide polymorphism (SNP) C > T (rs2273773) of the SIRT1 gene is a so-called «silent» mutation in exon 5 and may be linked to other mutations that affect both sirtuin-1 protein levels and its activity. The aim of the study was to assess the association of polymorphic variants rs2273773 of the sirtuin-1 gene with characteristics of insulin resistance and hormonal activity of adipose tissue in overweight patients with type 2 diabetes from the East Ukrainian population. Materials and methods. The study was conducted in accordance with international and domestic ethical and legal requirements and was approved by the Medical Ethics Committee at the IEPP. All examined patients underwent inpatient treatment at the institute's clinic. A retrospective analysis of clinical and biochemical parameters obtained for patients whose samples are included in the DNA collection of patients with type 2 diabetes mellitus (DM) was conducted. 61 patients with type 2 DM (male/female: 27/34) aged 53.35 ± 1.38 years, with diabetes duration of 5.33 ± 0.67 years, glycosylated hemoglobin level of 7.74 ± 0.19%, with body mass index of 33.28 ± 0.89 kg/m2, and with waist-to-hip ratio of 0.99 ± 0.01 were selected. Antidiabetic therapy included sulfonamides, biguanides, or their combinations. Clinical, biochemical, and enzyme-linked immunosorbent assay measurements were performed at the National Institute for Public Health and the Environment (Bilthoven, the Netherlands) within the framework of scientific cooperation. Insulin resistance was characterized by the HOMA-IR index, HOMA-IR/adiponectin, adiponectin/leptin, HOMA-IR/leptin, Adipo-IR and a number of other surrogate indices. The pathological impact of dyslipidemia was assessed by Castelli risk indices I and II and triglyceride-glucose index. Determination of the single-nucleotide substitution of cytosine for thymine in exon 5 of the SIRT1 gene rs2273773 (C > T) was carried out by polymerase chain reaction with two pairs of opposite primers. Electrophoretic fractionation determined the following genotypes for the rs2273773 (C > T) SIRT1 gene: CC — 314/228 bp; CT — 314/228/135 bp; TT — 314/135 bp. Allele frequencies for the studied genotype were calculated. The normality of the distribution of variables was determined using the Kolmogorov-Smirnov criterion. To compare the indicators characterized by normal distribution, the unpaired two-tailed Student's t-test was used, to compare the parameters with non-normal distribution, the Mann-Whitney test. To statistically assess the differences observed between the empirical and theoretical frequencies of the variation series, the χ2 (chi-square) test was used. Results. Genotyping according to the above-mentioned SNP indicates that there is no accumulation of certain genotypes under the conditions of the studied pathology. A preliminary analysis of the polymorphism functional significance was performed using a recessive inheritance model, i.e. CC-carriers (n = 24) versus CT + TT (n = 37). Analysis of clinical parameters revealed that this SNP did not have a statistically significant effect on the age of manifestation of type 2 DM, the degree of diabetes compensation, HOMA-IR, atherogenicity indices, blood pressure, and degree of obesity. However, there was a trend (0.05 < P < 0.1) towards worse indicators characterizing insulin resistance of adipose tissue (HOMA-IR/adiponectin, HOMA-IR/leptin, adiponectin/leptin) in carriers of the mutant T-allele. The above was accompanied by a shift in the triglyceride-glucose index (CC-carriers: 8.15 (4.29; 14.81) units vs 10.91 (6.88; 16.39) units in the CC + CT group, 0.05 < P < 0.1) and dyslipidemia parameters (triglycerides, high-density lipoprotein cholesterol). The mutant T-allele has been found to have a negative effect on indicators related to the hormonal function of adipose tissue. Thus, there is a statistically significant decrease in the levels of the most active form of anti-inflammatory adipocytokine — high molecular weight adiponectin — in T-allele carriers relative to the indicator for the CC genotype (1.96 ± 0.19 vs 3.09 ± 0.50 mg/L, respectively, P < 0.05). This was accompanied by a decrease in the levels of vaspin, an adipokine that increases insulin sensitivity, inhibits the synthesis of pro-inflammatory cytokines, and is involved in the regulation of food intake (CC-carriers: 0.33 (0.20; 0.64) vs 0.19 (0.08; 0.49) μg/L in the CC + CT group, P < 0.05). There are trends toward higher levels of chronic inflammation markers (TNF-α, IL-6, and IL-1b), which, however, do not reach statistical significance. In addition, carriers of the T-allele had significantly higher superoxide dismutase activity (24.77 ± 0.92 vs 20.46 ± 0.68 kU/mmol Hb in CC-carriers, P < 0.01) and levels of total (44.24 ± 3.45 vs 31.39 ± 2.96 μmol/mmol Hb in CC-carriers, P < 0.01) and reduced glutathione (35.10 ± 2.96 vs 21.86 ± 2.24 μmol/mmol Hb in CC-carriers, P < 0.01) in erythrocytes. The above is most likely compensatory in nature and indicates active lipoperoxidation processes. Conclusions. Analysis of the hormonal activity of adipose tissue suggests a higher cardiovascular risk in carriers of the minor allele of the C > T rs2273773 polymorphism of the sirtuin-1 gene among overweight patients with type 2 diabetes in the East Ukrainian population. The results obtained can be used to optimize prevention and treatment regimens for overweight individuals and patients with type 2 diabetes, which will help maintain working capacity and increase the duration and quality of life.
- Open Access
- 30 December 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (8) , 799-806
Adiponectin gene polymorphism +45 T>G ADIPOQ rs2241766 as one of the factors in the pharmacogenetics of type 2 diabetes mellitus
Background. Diabetes mellitus is a syndrome of various etiologies, characterized mainly by chronic hyperglycemia with disorders associated with protein and lipid metabolism. Numerous risk factors for the development of type 2 diabetes have been identified, the most important of which is the pathogenetic contribution of visceral obesity. Adipose tissue is now understood to be an active endocrine organ, secreting various hormones and cytokines that regulate metabolism and inflammation. The ADIPOQ gene located on chromosome 3q27, a region that recent scans of the entire human genome have suggested as a “type 2 diabetes susceptibility locus”, encodes the hormone adiponectin, which is derived from adipose tissue. The purpose of the study is to clarify the role of the adiponectin gene polymorphism +45 T>G ADIPOQ rs2241766 in the mechanisms of pharmacogenetic response in patients with obesity and type 2 diabetes, taking into account the assessment of its impact on the course and effectiveness of therapy. Materials and methods. Sixty-one people were selected for analysis. All patients received oral hypoglycemic drugs: sulfonamides, biguanides or their combination before hospitalization in the clinic. A comparative analysis of a number of biochemical parameters was conducted in the groups that took or did not take metformin as the main sugar-lowering drug, considering the single nucleotide polymorphism of the adiponectin gene. Results. The results indicate that the aforementioned drug has antioxidant properties, a certain hepatoprotective effect (a significant decrease in aspartate and alanine aminotransferase in G allele carriers who received the drug); also, the ability to improve the lipid profile, including in G allele carriers, has been statistically proven, that is, it has the potential to reduce the risk of developing cardiovascular complications, which is the main cause of death in patients. Conclusions. Genetic testing can be used to divide patients with type 2 diabetes and obesity into specific clusters and/or endophenotypes. Advances in the field of pharmacogenomics will allow clinicians to select personalized drug therapy regimens in order to increase its effectiveness and reduce the risk of developing adverse events.
- 30 December 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (8) , 799-806
Open AccessAdiponectin gene polymorphism +45 T>G ADIPOQ rs2241766 as one of the factors in the pharmacogenetics of type 2 diabetes mellitus
Background. Diabetes mellitus is a syndrome of various etiologies, characterized mainly by chronic hyperglycemia with disorders associated with protein and lipid metabolism. Numerous risk factors for the development of type 2 diabetes have been identified, the most important of which is the pathogenetic contribution of visceral obesity. Adipose tissue is now understood to be an active endocrine organ, secreting various hormones and cytokines that regulate metabolism and inflammation. The ADIPOQ gene located on chromosome 3q27, a region that recent scans of the entire human genome have suggested as a “type 2 diabetes susceptibility locus”, encodes the hormone adiponectin, which is derived from adipose tissue. The purpose of the study is to clarify the role of the adiponectin gene polymorphism +45 T>G ADIPOQ rs2241766 in the mechanisms of pharmacogenetic response in patients with obesity and type 2 diabetes, taking into account the assessment of its impact on the course and effectiveness of therapy. Materials and methods. Sixty-one people were selected for analysis. All patients received oral hypoglycemic drugs: sulfonamides, biguanides or their combination before hospitalization in the clinic. A comparative analysis of a number of biochemical parameters was conducted in the groups that took or did not take metformin as the main sugar-lowering drug, considering the single nucleotide polymorphism of the adiponectin gene. Results. The results indicate that the aforementioned drug has antioxidant properties, a certain hepatoprotective effect (a significant decrease in aspartate and alanine aminotransferase in G allele carriers who received the drug); also, the ability to improve the lipid profile, including in G allele carriers, has been statistically proven, that is, it has the potential to reduce the risk of developing cardiovascular complications, which is the main cause of death in patients. Conclusions. Genetic testing can be used to divide patients with type 2 diabetes and obesity into specific clusters and/or endophenotypes. Advances in the field of pharmacogenomics will allow clinicians to select personalized drug therapy regimens in order to increase its effectiveness and reduce the risk of developing adverse events.
- Open Access
- 30 December 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (8) , 873-882
Evaluation of the efficacy of metformin in prediabetes taking into account the metabolic characteristics of perimenopausal women: a literature review
This review aims to examine the efficacy of metformin in the prevention of type 2 diabetes mellitus (T2DM) in perimenopausal women with prediabetes. The authors emphasize that prediabetes is a serious condition that affects millions of people worldwide, with a high risk of progression to T2DM, especially in women. Therefore, early intervention is critical. The literature search methodology included a systematic review of scientific databases such as PubMed, Scopus, and Web of Science, using appropriate keywords to identify relevant publications. The article emphasizes that there are significant gaps in the study of the impact of prediabetes оn women during the perimenopausal period, which is characterized by pronounced hormonal fluctuations. Such insufficient research is problematic, since hormonal changes can significantly affect metabolism and the effectiveness of therapy. Metformin, despite its recognized role in the treatment of T2DM, exhibits multifaceted effects that go beyond simple glycemic control. The review systematizes data on its effects on weight loss and inflammation (metformin promotes the reduction of visceral fat, improves sensitivity to satiety hormones, and has anti-inflammatory effects); effects on endocrine axes (the drug modulates the hypothalamic-pituitary-ovarian and hypothalamic-pituitary-thyroid axes, and also reduces prolactin levels, these effects depend on dosage and estradiol levels); gynecological diseases (it is effectively used in polycystic ovary syndrome and the treatment of proliferative endometrial changes); and pharmacological profile (the authors review the mechanisms of action of metformin, including its effects on AMPK activation and interaction with the intestinal microbiota). The review highlights that, despite the established efficacy of metformin in the prevention of T2DM, data on its use in perimenopausal women are limited. This is due to the lack of targeted studies, as well as the need to take into account individual hormonal fluctuations. Thus, the authors emphasize the need for well-designed randomized controlled trials that would allow the development of personalized and effective therapeutic strategies for women with prediabetes during this period of life.
- 30 December 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (8) , 873-882
Open AccessEvaluation of the efficacy of metformin in prediabetes taking into account the metabolic characteristics of perimenopausal women: a literature review
This review aims to examine the efficacy of metformin in the prevention of type 2 diabetes mellitus (T2DM) in perimenopausal women with prediabetes. The authors emphasize that prediabetes is a serious condition that affects millions of people worldwide, with a high risk of progression to T2DM, especially in women. Therefore, early intervention is critical. The literature search methodology included a systematic review of scientific databases such as PubMed, Scopus, and Web of Science, using appropriate keywords to identify relevant publications. The article emphasizes that there are significant gaps in the study of the impact of prediabetes оn women during the perimenopausal period, which is characterized by pronounced hormonal fluctuations. Such insufficient research is problematic, since hormonal changes can significantly affect metabolism and the effectiveness of therapy. Metformin, despite its recognized role in the treatment of T2DM, exhibits multifaceted effects that go beyond simple glycemic control. The review systematizes data on its effects on weight loss and inflammation (metformin promotes the reduction of visceral fat, improves sensitivity to satiety hormones, and has anti-inflammatory effects); effects on endocrine axes (the drug modulates the hypothalamic-pituitary-ovarian and hypothalamic-pituitary-thyroid axes, and also reduces prolactin levels, these effects depend on dosage and estradiol levels); gynecological diseases (it is effectively used in polycystic ovary syndrome and the treatment of proliferative endometrial changes); and pharmacological profile (the authors review the mechanisms of action of metformin, including its effects on AMPK activation and interaction with the intestinal microbiota). The review highlights that, despite the established efficacy of metformin in the prevention of T2DM, data on its use in perimenopausal women are limited. This is due to the lack of targeted studies, as well as the need to take into account individual hormonal fluctuations. Thus, the authors emphasize the need for well-designed randomized controlled trials that would allow the development of personalized and effective therapeutic strategies for women with prediabetes during this period of life.
- Open Access
- 15 December 2025
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 82 (4) , 44-53
ЗВ'ЯЗОК МІЖ ПОРАНЕННЯМИ ВІЙСЬКОВОСЛУЖБОВЦІВ ТА РОЗВИТКОМ ЦУКРОВОГО ДІАБЕТУ (ОГЛЯД ЛІТЕРАТУРИ)
The article examines and systematizes the existing knowledge on the potential link between combat-related injuries in service members and the subsequent development of diabetes mellitus (DM). The aim of the study is to comprehensively analyze the possible physiological and psychological mechanisms underlying this association, as well as to review the available statistical data and scientific research in this field. A literature search was conducted using the databases Web of Science, Scopus, MedLine, etc. The results of the analysis indicate that certain types of injuries, in particular those accompanied by significant physical and psychological stress, traumatic brain injuries, amputations, or chronic inflammatory processes, may create a favorable environment for increasing the risk of developing DM in service members. These conditions are capable of inducing complex neuroendocrine and metabolic changes that disrupt the regulation of blood glucose levels and lead to insulin resistance. The authors emphasize the critical importance of timely identification of risk factors for DM in service members who have survived injuries. Regular medical examinations, including assessment of metabolic status and the presence of comorbidities, are necessary for early diagnosis and implementation of preventive measures. In addition, the promotion of a healthy lifestyle, including a balanced diet and sufficient physical activity, can play a significant role in reducing the likelihood of developing diabetes in this vulnerable population. Thus, the article emphasizes the need for further research to better understand the pathogenetic mechanisms linking injuries and diabetes in military personnel, as well as to develop effective strategies for medical support and prevention of this disease among veterans. The knowledge gained will contribute to the optimization of medical care and improvement of the quality of life of military personnel after returning from the combat zone.
- 15 December 2025
- Published by V.Danilevsky Institute for Endocrine Pathology Problems of NAMSU in PROBLEMS OF ENDOCRINE PATHOLOGY
- Vol. 82 (4) , 44-53
Open AccessЗВ'ЯЗОК МІЖ ПОРАНЕННЯМИ ВІЙСЬКОВОСЛУЖБОВЦІВ ТА РОЗВИТКОМ ЦУКРОВОГО ДІАБЕТУ (ОГЛЯД ЛІТЕРАТУРИ)
The article examines and systematizes the existing knowledge on the potential link between combat-related injuries in service members and the subsequent development of diabetes mellitus (DM). The aim of the study is to comprehensively analyze the possible physiological and psychological mechanisms underlying this association, as well as to review the available statistical data and scientific research in this field. A literature search was conducted using the databases Web of Science, Scopus, MedLine, etc. The results of the analysis indicate that certain types of injuries, in particular those accompanied by significant physical and psychological stress, traumatic brain injuries, amputations, or chronic inflammatory processes, may create a favorable environment for increasing the risk of developing DM in service members. These conditions are capable of inducing complex neuroendocrine and metabolic changes that disrupt the regulation of blood glucose levels and lead to insulin resistance. The authors emphasize the critical importance of timely identification of risk factors for DM in service members who have survived injuries. Regular medical examinations, including assessment of metabolic status and the presence of comorbidities, are necessary for early diagnosis and implementation of preventive measures. In addition, the promotion of a healthy lifestyle, including a balanced diet and sufficient physical activity, can play a significant role in reducing the likelihood of developing diabetes in this vulnerable population. Thus, the article emphasizes the need for further research to better understand the pathogenetic mechanisms linking injuries and diabetes in military personnel, as well as to develop effective strategies for medical support and prevention of this disease among veterans. The knowledge gained will contribute to the optimization of medical care and improvement of the quality of life of military personnel after returning from the combat zone.
- Open Access
- 29 September 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (6) , 619-625
The potential role of the MTHFR C677T polymorphism in the pathogenetic mechanisms of hormonal and metabolic response to antihyperglycemic therapy
Background. Type 2 diabetes mellitus (T2DM) is a multifactorial disease involving both environmental and genetic components. The methylenetetrahydrofolate reductase (MTHFR) gene, particularly the C677T polymorphism, influences folate metabolism and homocysteine levels and may affect metabolic processes and pharmacological response. Metformin is the first-line antihyperglycemic agent for T2DM, but interindividual variability in treatment response remains a key issue. The purpose of the work is to identify and assess the potential impact of a pathogenetically significant single-nucleotide polymorphism of the MTHFR gene on the development of obesity and type 2 diabetes mellitus in the implementation of the hormonal and metabolic effects of pharmacological factors. Materials and methods. This study included 28 patients with T2DM and metabolic syndrome (body mass index ≥ 30 kg/m2). Clinical, biochemical, and anthropometric parameters were assessed. Genotyping of the MTHFR C677T polymorphism was performed using polymerase chain reaction and restriction fragment length polymorphism. The effects of metformin therapy were evaluated by analyzing glycemic control, lipid profile, liver function, adipokine levels, and oxidative stress markers, taking into account the patients’ MTHFR genotypes. Results. Metformin use was associated with improved lipid profile in all genotypes. In addition, a genotype-specific reduction in liver enzyme activity was observed: aspartate aminotransferase levels decreased significantly in T allele carriers, while alanine aminotransferase reduced in patients with the CC genotype. These results suggest both pleiotropic and genotype-dependent hepatoprotective effects of metformin. No significant differences in MTHFR genotype distribution were found between metformin-treated and untreated groups. Conclusions. Metformin has beneficial metabolic effects in T2DM patients and may exert genotype-specific hepatoprotective properties. The C677T polymorphism of the MTHFR gene did not determine whether patients were prescribed metformin, but it may modulate liver-related biochemical responses to the drug. These findings support the relevance of pharmacogenetic approaches to optimize therapy in T2DM.
- 29 September 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (6) , 619-625
Open AccessThe potential role of the MTHFR C677T polymorphism in the pathogenetic mechanisms of hormonal and metabolic response to antihyperglycemic therapy
Background. Type 2 diabetes mellitus (T2DM) is a multifactorial disease involving both environmental and genetic components. The methylenetetrahydrofolate reductase (MTHFR) gene, particularly the C677T polymorphism, influences folate metabolism and homocysteine levels and may affect metabolic processes and pharmacological response. Metformin is the first-line antihyperglycemic agent for T2DM, but interindividual variability in treatment response remains a key issue. The purpose of the work is to identify and assess the potential impact of a pathogenetically significant single-nucleotide polymorphism of the MTHFR gene on the development of obesity and type 2 diabetes mellitus in the implementation of the hormonal and metabolic effects of pharmacological factors. Materials and methods. This study included 28 patients with T2DM and metabolic syndrome (body mass index ≥ 30 kg/m2). Clinical, biochemical, and anthropometric parameters were assessed. Genotyping of the MTHFR C677T polymorphism was performed using polymerase chain reaction and restriction fragment length polymorphism. The effects of metformin therapy were evaluated by analyzing glycemic control, lipid profile, liver function, adipokine levels, and oxidative stress markers, taking into account the patients’ MTHFR genotypes. Results. Metformin use was associated with improved lipid profile in all genotypes. In addition, a genotype-specific reduction in liver enzyme activity was observed: aspartate aminotransferase levels decreased significantly in T allele carriers, while alanine aminotransferase reduced in patients with the CC genotype. These results suggest both pleiotropic and genotype-dependent hepatoprotective effects of metformin. No significant differences in MTHFR genotype distribution were found between metformin-treated and untreated groups. Conclusions. Metformin has beneficial metabolic effects in T2DM patients and may exert genotype-specific hepatoprotective properties. The C677T polymorphism of the MTHFR gene did not determine whether patients were prescribed metformin, but it may modulate liver-related biochemical responses to the drug. These findings support the relevance of pharmacogenetic approaches to optimize therapy in T2DM.
- Open Access
- 29 September 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (6) , 646-655
Continuous glucose monitoring using wearable devices: technological achievements and world trends
Diabetes is a long-term disease characterized by elevated blood glucose levels, potentially damaging multiple organs and systems. Monitoring glucose levels, whether continuous or intermittent, is essential not only for people with diabetes but also for the general population. Although the past decade has brought significant advances in glucose monitoring technologies through the work of researchers and manufacturers, the field of glucose biosensors still faces significant challenges. A thorough literature search was conducted in the scientific databases Scopus, Science Direct (by Elsevier), and PubMed, including MEDLINE, to prepare this work. The following keywords were used for the search: “glucose monitoring”, “continuous glucose monitoring”, “wearable devices”, “glucose biosensors”, “diabetes”, “artificial intelligence in diabetes”, and “personalized medicine”. In this article, the authors review in detail the latest developments in glucose monitoring, including invasive, minimally invasive, and noninvasive approaches. The integration of electronic components, wireless communication technologies, energy harvesting systems were analyzed, and limitations of current solutions were assessed. Additionally, the potential of combining medical data from continuous glucose monitors with artificial intelligence techniques is highlighted to develop accurate diabetes treatment protocols. This approach provides high accuracy of results with short-term prediction based on time series of glucose readings. The authors highlight the urgent need for further improvement of glucose monitoring technologies, which is crucial for optimizing diabetes therapy and meeting important clinical demands for advanced monitoring solutions with practical applications.
- 29 September 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (6) , 646-655
Open AccessContinuous glucose monitoring using wearable devices: technological achievements and world trends
Diabetes is a long-term disease characterized by elevated blood glucose levels, potentially damaging multiple organs and systems. Monitoring glucose levels, whether continuous or intermittent, is essential not only for people with diabetes but also for the general population. Although the past decade has brought significant advances in glucose monitoring technologies through the work of researchers and manufacturers, the field of glucose biosensors still faces significant challenges. A thorough literature search was conducted in the scientific databases Scopus, Science Direct (by Elsevier), and PubMed, including MEDLINE, to prepare this work. The following keywords were used for the search: “glucose monitoring”, “continuous glucose monitoring”, “wearable devices”, “glucose biosensors”, “diabetes”, “artificial intelligence in diabetes”, and “personalized medicine”. In this article, the authors review in detail the latest developments in glucose monitoring, including invasive, minimally invasive, and noninvasive approaches. The integration of electronic components, wireless communication technologies, energy harvesting systems were analyzed, and limitations of current solutions were assessed. Additionally, the potential of combining medical data from continuous glucose monitors with artificial intelligence techniques is highlighted to develop accurate diabetes treatment protocols. This approach provides high accuracy of results with short-term prediction based on time series of glucose readings. The authors highlight the urgent need for further improvement of glucose monitoring technologies, which is crucial for optimizing diabetes therapy and meeting important clinical demands for advanced monitoring solutions with practical applications.
- Open Access
- 25 June 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (4) , 433-440
Smart diabetes management: remote monitoring and predictive health insights
The article explores how modern technology is revolutionizing diabetes care by integrating continuous glucose monitoring (CGM), predictive analytics, and remote healthcare solutions. With over 500 million people globally affected by diabetes, and rising prevalence in countries like Ukraine, effective and adaptive management is critical. The goal of this paper is to present how modern technologies, specifically the GluComp platform, enhance diabetes management by integrating continuous glucose monitoring and personalized machine learning models. It aims to demonstrate how real-time data, predictive analytics, and modular design enable proactive and adaptive care for patients with diabetes. Traditional diabetes monitoring methods, such as fingerstick blood tests, are limited in providing real-time data. Newer CGM technologies like Dexcom and Freestyle Libre enable continuous, non-invasive monitoring of glucose levels, producing time series data essential for detecting patterns and predicting dangerous fluctuations (hypo- or hyperglycemia). The use of deep learning and neural network algorithms enhances the accuracy of these predictions by capturing complex data trends over time. A key innovation discussed is GluComp, a modular digital health platform designed to improve diabetes management. GluComp integrates CGM systems with personalized machine learning models to deliver real-time alerts, predictive insights, and adaptive care. It supports offline functionality for rural or under-resourced areas, and offers intuitive dashboards for patients and healthcare providers, boosting engagement and treatment adherence. The article also addresses the challenges in Ukraine’s healthcare system, especially for diabetes patients in economically disadvantaged or rural areas, where access to CGMs and insulin pumps is limited due to high costs. Despite these challenges, progress is being made through public health initiatives, mobile health apps, and government support programs aimed at increasing awareness and access to care. Special attention is given to the military population, for whom CGM technology could be critical due to high physical and psychological stress levels, irregular routines, and limited access to immediate medical care. Implementing CGM in military settings could enhance operational readiness and transfer innovations to civilian healthcare. Smart diabetes management using platforms like GluComp — through real-time monitoring, predictive modeling, and personalized care — is a transformative step in chronic disease management. It holds promise for improving outcomes, reducing complications, and enhancing quality of life, especially when adapted to meet the needs of underserved populations.
- 25 June 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (4) , 433-440
Open AccessSmart diabetes management: remote monitoring and predictive health insights
The article explores how modern technology is revolutionizing diabetes care by integrating continuous glucose monitoring (CGM), predictive analytics, and remote healthcare solutions. With over 500 million people globally affected by diabetes, and rising prevalence in countries like Ukraine, effective and adaptive management is critical. The goal of this paper is to present how modern technologies, specifically the GluComp platform, enhance diabetes management by integrating continuous glucose monitoring and personalized machine learning models. It aims to demonstrate how real-time data, predictive analytics, and modular design enable proactive and adaptive care for patients with diabetes. Traditional diabetes monitoring methods, such as fingerstick blood tests, are limited in providing real-time data. Newer CGM technologies like Dexcom and Freestyle Libre enable continuous, non-invasive monitoring of glucose levels, producing time series data essential for detecting patterns and predicting dangerous fluctuations (hypo- or hyperglycemia). The use of deep learning and neural network algorithms enhances the accuracy of these predictions by capturing complex data trends over time. A key innovation discussed is GluComp, a modular digital health platform designed to improve diabetes management. GluComp integrates CGM systems with personalized machine learning models to deliver real-time alerts, predictive insights, and adaptive care. It supports offline functionality for rural or under-resourced areas, and offers intuitive dashboards for patients and healthcare providers, boosting engagement and treatment adherence. The article also addresses the challenges in Ukraine’s healthcare system, especially for diabetes patients in economically disadvantaged or rural areas, where access to CGMs and insulin pumps is limited due to high costs. Despite these challenges, progress is being made through public health initiatives, mobile health apps, and government support programs aimed at increasing awareness and access to care. Special attention is given to the military population, for whom CGM technology could be critical due to high physical and psychological stress levels, irregular routines, and limited access to immediate medical care. Implementing CGM in military settings could enhance operational readiness and transfer innovations to civilian healthcare. Smart diabetes management using platforms like GluComp — through real-time monitoring, predictive modeling, and personalized care — is a transformative step in chronic disease management. It holds promise for improving outcomes, reducing complications, and enhancing quality of life, especially when adapted to meet the needs of underserved populations.
- Open Access
- 1 April 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (2) , 121-127
Metabolic status and genetic features of one-carbon metabolism in psoriasis patients during antimetabolite-based therapy
Background. The purpose was to evaluate the metabolic status of patients with psoriasis depending on the genotype of single-nucleotide polymorphisms (SNP) C677T and A1298C of the MTHFR gene with methotrexate treatment. Materials and methods. 77 patients with psoriasis were included in the study. Their genotypes based on polymorphic variants of the MTHFR gene were determined by the PCR-RFLP. Biochemical indicators were evaluated before and after treatment with methotrexate. Correspondence to the law of normal distribution was verified before further statistical analysis using the T-test, Kolmogorov-Smirnov, Shapiro-Wilk, Wilcoxon tests; Pearson correlation coefficients were calculated. Results. The difference between ALT levels before (0.60 ± 0.04) and after (0.74 ± 0.06) treatment in patients with CT genotype for SNP C677T of the MTHFR gene who received methotrexate is significant (p < 0.008), while in those with CC and TT genotypes, no significant difference was noted. No significant difference was found between AST levels before and after methotrexate treatment in patients with all genotypes — CC, CT and TT. Also, in participants with CT genotype for C677T MTHFR, a significant increase in bilirubin, creatinine, urea was noted after treatment with methotrexate. Carriers of genotype TT on C677T polymorphism of the MTHFR gene after treatment with methotrexate also showed a significant increase in bilirubin, creatinine, α-amylase, urea. In patients with the AA genotype for A1298C polymorphism of the MTHFR gene, the level of all serum biochemical indicators after methotrexate therapy changed significantly (p < 0.05–0.001): α-amylase and total protein decreased, and the levels of other indicators increased. Our study demonstrated that AA genotype on MTHFR A1298C is associated with elevated level of ALT after methotrexate treatment — by almost 1.3 times. No significant changes in any of the indicators were observed in patients with AC genotype after treatment. An analysis was carried out of the relationship between pathological enlargement of the liver — hepatomegaly, diffuse liver diseases and genotypes for SNP C677T and A1298C MTHFR in patients with psoriasis. A negative correlation was found between the number of polymorphic alleles in the patient’s genotype and hepatomegaly (r = –0.91, p = 0.009). The highest increase (14.50 ± 5.37 mm) in the size of the liver is observed in patients with the CCAA genotype, which is prognostically most favorable for the development of psoriasis and its complications. The smallest enlargement of the liver (6.40 ± 2.44 mm) was found in patients with the TTAA genotype, which is a risk factor for the development of psoriasis and side effects during methotrexate therapy. Both single-locus and haplotype analysis suggest that the MTHFR gene polymorphism has an effect during methotrexate therapy in psoriasis patients. It is important to predict the results of pharmacotherapy taking into account personal molecular genetic markers. Conclusions. Assessment of the condition of the liver after treatment with methotrexate showed an inverse relation between an increase in its size and the presence of polymorphic alleles in the patients’ genotype. The highest increase in liver size is observed in patients with the CCAA genotype. Probably, the genotype, in particular CC, allows taking methotrexate for a certain time without significant complications, which affects the condition and characteristics of the liver over time.
- 1 April 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (2) , 121-127
Open AccessMetabolic status and genetic features of one-carbon metabolism in psoriasis patients during antimetabolite-based therapy
Background. The purpose was to evaluate the metabolic status of patients with psoriasis depending on the genotype of single-nucleotide polymorphisms (SNP) C677T and A1298C of the MTHFR gene with methotrexate treatment. Materials and methods. 77 patients with psoriasis were included in the study. Their genotypes based on polymorphic variants of the MTHFR gene were determined by the PCR-RFLP. Biochemical indicators were evaluated before and after treatment with methotrexate. Correspondence to the law of normal distribution was verified before further statistical analysis using the T-test, Kolmogorov-Smirnov, Shapiro-Wilk, Wilcoxon tests; Pearson correlation coefficients were calculated. Results. The difference between ALT levels before (0.60 ± 0.04) and after (0.74 ± 0.06) treatment in patients with CT genotype for SNP C677T of the MTHFR gene who received methotrexate is significant (p < 0.008), while in those with CC and TT genotypes, no significant difference was noted. No significant difference was found between AST levels before and after methotrexate treatment in patients with all genotypes — CC, CT and TT. Also, in participants with CT genotype for C677T MTHFR, a significant increase in bilirubin, creatinine, urea was noted after treatment with methotrexate. Carriers of genotype TT on C677T polymorphism of the MTHFR gene after treatment with methotrexate also showed a significant increase in bilirubin, creatinine, α-amylase, urea. In patients with the AA genotype for A1298C polymorphism of the MTHFR gene, the level of all serum biochemical indicators after methotrexate therapy changed significantly (p < 0.05–0.001): α-amylase and total protein decreased, and the levels of other indicators increased. Our study demonstrated that AA genotype on MTHFR A1298C is associated with elevated level of ALT after methotrexate treatment — by almost 1.3 times. No significant changes in any of the indicators were observed in patients with AC genotype after treatment. An analysis was carried out of the relationship between pathological enlargement of the liver — hepatomegaly, diffuse liver diseases and genotypes for SNP C677T and A1298C MTHFR in patients with psoriasis. A negative correlation was found between the number of polymorphic alleles in the patient’s genotype and hepatomegaly (r = –0.91, p = 0.009). The highest increase (14.50 ± 5.37 mm) in the size of the liver is observed in patients with the CCAA genotype, which is prognostically most favorable for the development of psoriasis and its complications. The smallest enlargement of the liver (6.40 ± 2.44 mm) was found in patients with the TTAA genotype, which is a risk factor for the development of psoriasis and side effects during methotrexate therapy. Both single-locus and haplotype analysis suggest that the MTHFR gene polymorphism has an effect during methotrexate therapy in psoriasis patients. It is important to predict the results of pharmacotherapy taking into account personal molecular genetic markers. Conclusions. Assessment of the condition of the liver after treatment with methotrexate showed an inverse relation between an increase in its size and the presence of polymorphic alleles in the patients’ genotype. The highest increase in liver size is observed in patients with the CCAA genotype. Probably, the genotype, in particular CC, allows taking methotrexate for a certain time without significant complications, which affects the condition and characteristics of the liver over time.